Monash Scientists Find an Immune Enzyme That Ages the Heart, Liver and Kidneys, and Mice Without It Kept Healthier Organs Even as Their Immune Systems Grew Old

For decades, scientists have treated the aging immune system and aging organs as two sides of the same coin: as immune cells wear out and inflammation creeps up, tissues are assumed to decline with them. A study from Australia’s Monash University suggests the two can be pulled apart. Researchers have tied a single immune-cell enzyme, Granzyme K, to age-related damage in the heart, liver and kidneys, and found that old mice lacking it kept noticeably healthier organs even though their immune systems aged on schedule.

The work, led by senior author Professor Nicole La Gruta of the Monash Biomedicine Discovery Institute, was published in the journal Immunity and announced by the university on November 13. Nature flagged it as a research highlight, and Xinhua carried the news on November 14.

What the Researchers Found

Granzyme K is a protein-cutting enzyme made by immune cells. According to Monash’s announcement, its levels are already known to rise substantially with age in both mice and people, but its role in organ aging had been unclear.

To test it, the team compared older mice that had been engineered to lack Granzyme K with normal mice. The results, as Monash describes them:

  • Heart: mice without the enzyme showed significantly better heart function and less fibrosis, the scarring that stiffens tissue and degrades how well an organ works.
  • Kidneys: normal aging brought enlarged filtering units and heavy buildup of inflammatory complement proteins; both were markedly reduced in the knockout mice.
  • Liver: signs of age-related damage were also reduced. A summary by AgingResearch.News notes that liver function improved and fibrosis fell through a route that did not depend on complement.

The headline result is what did not change. The knockout mice still showed major features of immune aging, including impaired T-cell function. “This challenges the long-held assumption that organ and immune ageing are inextricably linked,” La Gruta said in the university’s statement. The authors concluded that Granzyme K drives tissue aging but not immune aging or body-wide chronic inflammation.

The team also looked beyond mice. In human datasets, they found elevated Granzyme K in patients with several inflammatory and fibrotic conditions, including lupus nephritis and heart failure.

How It Fits With Earlier Work

The finding builds on a growing body of research putting Granzyme K under the microscope. In February 2025, a team publishing in Nature showed that the enzyme can switch on the entire complement cascade, a branch of the immune system that tags and attacks tissue, and that mice lacking it were significantly protected from arthritis and dermatitis. The Monash study’s kidney results, with less complement buildup in the knockout animals, are consistent with that mechanism, while the liver results suggest the enzyme has more than one way of doing damage.

For the longevity field, the significance is conceptual. Much of today’s “inflammaging” research aims to calm the low-grade inflammation that comes with age. If organ damage can be slowed without touching overall immune aging, drug developers may be able to aim at a narrower target, potentially with fewer trade-offs for the body’s defenses. Nature’s research highlight framed it in those terms: drugs that lower the enzyme might one day counter the effects of aging without impairing immune protection.

The Caveats Are Real

This is early, preclinical science, and the researchers say so plainly. The mice lived their entire lives without Granzyme K, so the study does not show what happens if the enzyme is blocked in middle or old age, after damage has started. “We now need to understand whether blocking the protein later in life could achieve similar benefits,” La Gruta said, adding that further research is needed to know whether the effects carry over to humans. The team is now investigating ways to selectively block the enzyme.

There is also no approved drug that selectively targets Granzyme K today. Any therapy would need to clear years of safety testing, particularly because granzymes are part of how the immune system fights infections and tumors.

Why It Matters for Business Readers

The cost of organ aging is enormous. Kidney disease alone shows the scale. The CDC estimates that more than 1 in 10 U.S. adults, about 37 million people, have chronic kidney disease, and that roughly 87% of adults with CKD don’t know they have it. Age is one of the biggest risk factors, which is why a mechanism that links aging directly to kidney, heart and liver scarring draws attention from insurers, employers and drugmakers alike.

Fibrosis is a crowded but unsolved market. Scarring in the heart, liver and kidneys underlies several of the costliest chronic diseases. A target that appears to drive fibrosis in multiple organs at once could interest companies working on heart failure, kidney disease and liver disease, even before anyone tries to sell it as an “anti-aging” drug. That matters because regulators do not recognize aging itself as a disease, so longevity biotechs typically enter the clinic through a specific condition first.

Investors should read it as a lead, not a product. A mouse knockout study is the starting line. The questions that will decide commercial value, including whether late-life blocking works, whether it is safe, and whether human biology behaves the same way, are still open. For employers and benefits leaders, the practical takeaway is unchanged: early screening for kidney and heart disease remains one of the cheapest ways to limit long-term costs while science like this matures.

The Bottom Line

Monash’s results point to Granzyme K as a possible switch for organ aging that operates separately from the immune system’s own decline. If later studies show the enzyme can be safely blocked in older animals and eventually in people, it could open a new route to keeping hearts, livers and kidneys healthier for longer. For now, it is a promising lead with a long road ahead.

Sources: Monash University, Immunity (Kannangara et al., 2026), Nature research highlight, Xinhua, AgingResearch.News, Nature (Donado et al., 2025), CDC.

Never miss a patient or client call. Clinics, wellness practices and health-focused businesses can’t afford a missed call when people are looking for care. MAJ.COM Voice AI runs 24/7 AI voice agents that answer every inbound call and handle outbound sales and customer support, so you never miss a lead. See how MAJ.COM Voice AI works →

Edited by Coron @QUE.COM
Website: https://QUE.COM Intelligence
Sponsored by: https://MAJ.COM AI Autonomous


Discover more from QUE.com

Subscribe to get the latest posts sent to your email.

Coron @QUE.COM

Editor at QUE.com Intelligence.

coronquecom has 153 posts and counting.See all posts by coronquecom

Leave a Reply

Connect with

Discover more from QUE.com

Subscribe now to keep reading and get access to the full archive.

Continue reading